Search
VO659
go.drugbank.com/drugs/DB18160InvestigationalVO659 is an antisense oligonucleotide being investigated for the treatment of Huntington's disease.
Synonyms: an antisense oligonucleotide that has been developed to target expanded CAG repeats in messenger ribonucleic acid (mRNA)VG161
go.drugbank.com/drugs/DB18469InvestigationalVG161 is an oncolytic virus therapy under investigation for the treatment of cholangiocarcinoma.
BG1805
go.drugbank.com/drugs/DB18667InvestigationalBG1805 is an investigational anti-CLL1 chimeric antigen receptor (CAR) T-cell therapy.
Izokibep
go.drugbank.com/drugs/DB19081InvestigationalIzokibep is under investigation in clinical trial NCT05623345 (Psoriatic Arthritis Study of Izokibep).
Gosogliptin
go.drugbank.com/drugs/DB08382InvestigationalGosogliptin has been used in trials studying the treatment of Renal Insufficiency, Chronic.
Contezolid
go.drugbank.com/drugs/DB12796InvestigationalMRX-I has been used in trials studying the treatment of Bacterial Infections.
D-Glutamic Acid
go.drugbank.com/drugs/DB02517ExperimentalGlutamic acid is the most common excitatory neurotransmitter in the central nervous system.
BGB-DXP593
go.drugbank.com/drugs/DB16357Investigational[L27401] It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants
Tasurgratinib
go.drugbank.com/drugs/DB21222InvestigationalThe usage of the INN stem '-gratinib' in the name indicates that Tasurgratinib is a fibroblast growth factor receptor (FGFR) inhibitor. … Tasurgratinib is under investigation in clinical trial NCT04962867 (NCCH2006/MK010 Trial (FORTUNE Trial)). Tasurgratinib has a monoisotopic molecular weight of 587.27 Da.
Synonyms: E 7090Ledaborbactam etzadroxil
go.drugbank.com/drugs/DB21455InvestigationalThe usage of the INN stem '-bactam' in the name indicates that Ledaborbactam etzadroxil is a ẞ-lactamase inhibitor. … Ledaborbactam etzadroxil is under investigation in clinical trial NCT06733675 (Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination).